BCR and diffuse large B-cell lymphoma: MYD88L265P-mutated ABC-DLBCL tumors with concomitant mutation in BCR signaling component CD79A/B responded to ibrutinib (80% response rate), but tumors harboring the MYD88L265P mutation with wild-type CD79A/B were resistant to ibrutinib, suggesting that these tumors could probably use MYD88-dependent survival signaling [34].